Core Insights - Pacira BioSciences Inc. (NASDAQ:PCRX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company presented data at the AAOS 2026 Annual Meeting, showcasing Exparel's benefits in pain management, including improved outcomes, reduced opioid use, and shorter hospital stays compared to standard treatments [1] - Iovera demonstrated longer-lasting pain relief and functional improvement, with benefits lasting up to 12 months, reinforcing the company's position in post-surgical pain management [3] Legislative Impact - A survey conducted by the Voices for Non-Opioid Choices coalition revealed the initial effects of the NOPAIN Act, which was implemented on January 1, 2025 [4][5] - 85% of facility representatives surveyed were aware of the NOPAIN Act, and over half of the facilities have made changes to increase the use of non-opioid options [5] - More than 80% of those surveyed reported a reduction in opioid prescribing for immediate post-surgery and discharge due to the legislation [5] Company Focus - Pacira BioSciences is dedicated to developing and marketing non-opioid pain management and regenerative health solutions, with a portfolio that includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device [6]

Financial Data and Key Metrics Changes - In 2025, the company achieved $726 million in revenue, marking a significant increase compared to previous years, with the highest gross margins in its history at 80% for Q4 2025, up from 79% in Q4 2024 [5][20] - The fourth quarter sales for EXPAREL increased to $155.8 million from $147.7 million in 2024, reflecting a volume growth of approximately 7% [19] - Non-GAAP R&D expenses rose to $34.4 million in Q4 2025 from $22.0 million in the previous year, while SG&A expenses increased to $91.9 million from $70.6 million [21] Business Line Data and Key Metrics Changes - EXPAREL showed solid performance with volume-based growth driven by expanding education and awareness, increasing commercial payer adoption, and growing demand across care sites [6][19] - ZILRETTA sales remained flat at $33 million in Q4 2025 compared to 2024, while iovera sales grew to $7 million from $6.5 million [19] Market Data and Key Metrics Changes - The company ended 2025 with 102 million lives covered outside of the surgical bundle, indicating a significant shift in payer policies and access to EXPAREL [7][16] - The strategic focus on key markets with high procedural volumes resulted in over 7% volume growth in these markets compared to 2024 [16] Company Strategy and Development Direction - The company is advancing its 5x30 strategy, aiming to help 3 million patients annually by 2030, with a clear focus on innovative, non-opioid pain management therapies [5][12] - Partnerships with J&J MedTech and LG Chem are expected to enhance market access and revenue growth, with LG Chem set to commercialize EXPAREL in select Asia Pacific countries [9][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting the successful execution of the NOPAIN Act and its positive impact on non-opioid stewardship [13][15] - The company anticipates steady top-line growth in 2026, with total revenue guidance set between $745 million and $770 million, and EXPAREL sales expected to be between $600 million and $620 million [23][24] Other Important Information - The company has strengthened its intellectual property estate to 21 patents, providing a solid foundation for EXPAREL's sustained growth [8] - The company executed $150 million in stock repurchases, reducing outstanding shares to approximately 41 million [22] Q&A Session Summary Question: What constitutes a clinically meaningful signal for the OA readout? - Management clarified that the primary focus of the PCRX-201 trial is safety, but they will also look for efficacy trends measured by key secondary endpoints [28][30] Question: What factors could lead to higher or lower EXPAREL sales guidance? - Management indicated that the guidance reflects a cautious approach due to potential headwinds in the elective procedure market, while also highlighting the positive indicators from their investments [37][39] Question: What are the barriers to adoption for EXPAREL? - Management noted that while reimbursement is improving, the focus is now on clinical adoption and ensuring that economic stakeholders recognize the value of EXPAREL [51][56] Question: What headwinds affected ZILRETTA's performance in 2025? - Management explained that prioritizing EXPAREL led to some disruption in ZILRETTA sales, but they expect growth in 2026 with a fully trained J&J sales team [59][61] Question: Will unexpected business development costs continue? - Management acknowledged that while there may be occasional unexpected costs, they are focused on disciplined investments that maximize shareholder value [65][68]

Core Viewpoint - Scilex Holding Company has made a strategic investment of $20 million in Quantum Scan Holdings, Inc. to support the development of innovative medical technologies aimed at improving healthcare delivery and efficiency [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][6]. - The company targets high unmet needs and large market opportunities with its non-opioid therapies [4]. Investment Details - The investment in Quantum Scan is intended to enhance the development of advanced diagnostic platforms and scalable healthcare solutions [2]. - Scilex believes this investment aligns with its strategic priorities and complements its previous investment in Datavault AI [2][3]. Quantum Scan Holdings, Inc. - Quantum Scan is a medical technology company focused on developing advanced healthcare technologies, including diagnostics and analytics [7]. - The company aims to enhance healthcare delivery and accessibility through innovative medical platforms [7]. Leadership Comments - Mustaq Patel, CEO of Quantum Scan, expressed gratitude for Scilex's investment, emphasizing the need for innovation in medical technologies [3]. - Henry Ji, CEO of Scilex, highlighted Quantum Scan's experienced team and the potential for long-term value creation through this investment [3].

Core Insights - ZYUS Life Sciences Corporation announced favorable preliminary results from its Phase 2a UTOPIA-1 trial, which evaluates Trichomylin® softgel capsules for managing cancer-related pain [1][2] Group 1: Trial Overview - UTOPIA-1 is a single-arm, proof-of-concept study focused on the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain [2] - Preliminary results are based on data from the first 25% of enrolled patients who have completed treatment [2] Group 2: Preliminary Findings - Early data suggest a reduction in average daily pain, pain interference, and pain severity [5] - There was a reduction in opioid dosing for breakthrough pain, indicating potential benefits of Trichomylin® [5] - No serious adverse events related to Trichomylin® softgel capsules were reported, and the capsules were generally well tolerated [5] Group 3: Company Commitment and Future Outlook - The company emphasizes its commitment to developing non-opioid alternatives for pain management and aims to secure regulatory approval for its innovative therapies [3] - The positive preliminary findings reflect over seven years of scientific research and clinical development, reinforcing the potential of Trichomylin® to address cancer-related pain [2][3]

Core Insights - Scilex Holding Company announced the confirmed claim process for the Dream Bowl 2026 Meme Coins, set to begin on December 24, 2025, for eligible shareholders [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products aimed at treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][6]. - The company targets high unmet needs in the market with its non-opioid therapies, aiming to improve patient outcomes [4]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief [4]. - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [4]. - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [4]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for treating lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [5]. - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [5].

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 19, 2025 Registration No. 333-290995 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Semnur Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1659463 (Primary Standard Industrial Classification Code Number) Pa ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Henry Ji, Ph.D. Chief Executive Officer, President & Chairperson 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Na ...

Core Insights - Cumberland Pharmaceuticals has announced that its Caldolor (ibuprofen) Injection is now associated with a permanent J-code (J1741) and a reimbursement price, providing a CMS-covered non-opioid option for pain and fever management [1][2][5] Group 1: Product Update - Caldolor is now linked to an established reimbursement price, allowing healthcare providers to access a reimbursable non-opioid alternative for pain management [3] - The product is indicated for managing mild to moderate pain and as an adjunct for moderate to severe pain, as well as for fever reduction [4] Group 2: Industry Context - The introduction of Caldolor as a non-opioid alternative is significant in the context of the ongoing opioid crisis, supporting safer pain management strategies [2] - The update aligns with opioid-sparing initiatives, helping healthcare providers make clinically appropriate decisions [3] Group 3: Company Overview - Cumberland Pharmaceuticals is the largest biopharmaceutical company based in Tennessee, focusing on unique products that enhance patient care [5] - The company’s portfolio includes several FDA-approved products, with Caldolor being a key offering [6]

Core Viewpoint - Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds, which will be used for working capital and general corporate purposes [1][4]. Group 1: Warrants and Proceeds - The company exercised two sets of existing warrants, totaling 904,396 shares, at a reduced exercise price of $22.51 per share [1]. - The April 2024 Warrants were originally priced at $38.50 per share, while the December 2024 Warrants had an exercise price of $22.72 per share [1]. - The gross proceeds from the exercise of these warrants were approximately $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company issued a new unregistered warrant for 1,356,594 shares at an exercise price of $29.00 per share, which is exercisable immediately and has a five-year term [3]. - The new warrant was offered in a private placement under Section 4(a)(2) of the Securities Act and Regulation D [5]. Group 3: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [9][10]. - Scilex has three product candidates in development, including SP-102, SP-103, and SP-104, which are aimed at various pain management indications [10].

Core Viewpoint - Scilex Holding Company has entered into a definitive agreement to exercise existing warrants, which is expected to generate approximately $20.3 million in gross proceeds for the company [1][4]. Group 1: Existing Warrants - The company will exercise a total of 428,572 shares from April 2024 Warrants at an exercise price of $38.50 per share and 475,824 shares from December 2024 Warrants at an exercise price of $22.72 per share [1]. - The aggregate gross proceeds from the exercise of these existing warrants are anticipated to be around $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company will issue a new unregistered warrant to purchase up to 1,356,594 shares of common stock at an exercise price of $29.00 per share [3]. - The new warrant will be exercisable immediately upon issuance and will have a term of five years [3]. Group 3: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [4]. Group 4: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [7][8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [8][9].